Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease

被引：6

作者：

Al Sulais, Eman ^{[1
]}

AlAmeel, Turki ^{[2
]}

机构：

[1] Royal Commiss Hosp, Dept Med, POB 496, Jubail Ind City 31911, Qatif, Saudi Arabia

[2] King Fahad Specialist Hosp, Dept Med, Dammam, Saudi Arabia

来源：

BIOLOGICS-TARGETS & THERAPY | 2020年 / 14卷

关键词：

biosimilars; inflammatory bowel disease; tumor necrosis factor inhibitors; ACTIVE RHEUMATOID-ARTHRITIS; CROHNS-DISEASE; DOUBLE-BLIND; INNOVATOR INFLIXIMAB; POSITION STATEMENT; ULCERATIVE-COLITIS; PARALLEL-GROUP; ANTIBODIES; EFFICACY; SAFETY;

D O I：

10.2147/BTT.S236433

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Anti- tumor Necrosis Factor (anti-TNF) agents are the backbone treatment of moderate to severe cases of inflammatory bowel disease. One of the main drawbacks of these agents is the high cost. The introduction of biosimilar products to anti-TNF agents is expected to lower the cost. Health care providers ought to be aware of the available data that addresses the safety and efficacy of biosimilars in IBD patients. This article outlines the current evidence-based data regarding the available biosimilar products, their safety, efficacy and how to deal with patients' concerns.

引用

页码：1 / 11

页数：11

共 50 条

[21] Association of Survivin Promoter Polymorphisms with Inflammatory Bowel Disease and Response to Antitumor Necrosis Factor Therapy
Rapti, Emmanouela
Gazouli, Maria
Legaki, Evangelia
Karamanolis, George
Thomas, Diamantis
Marinos, Evangelos
Papaconstantinou, Ioannis
GENETIC TESTING AND MOLECULAR BIOMARKERS, 2015, 19 (06) : 339 - 343
[22] Induction therapeutic drug monitoring of antitumor necrosis factor agents in inflammatory bowel disease: A pharmacist-led pilot study (INITIATE)
Inserra, V.
Monitto, C.
Friedman, A.
Gibson, D.
Harris, K.
Little, R.
Poole, S.
Smith, R.
Stokar, R.
Taylor, K.
Turbayne, A.
Ward, M.
Coutsouvelis, J.
Sparrow, M.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 157 - 158
[23] Biosimilars in paediatric inflammatory bowel disease
Sieczkowska-Golub, Joanna
Jarzebicka, Dorota
Oracz, Grzegorz
Kierkus, Jaroslaw
WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (35) : 4021 - 4027
[24] Biosimilars for the Treatment of Inflammatory Bowel Disease
Rudrapatna, Vivek A.
Velayos, Fernando
PRACTICAL GASTROENTEROLOGY, 2019, 43 (04) : 84 - 91
[25] Biosimilars in paediatric inflammatory bowel disease
Joanna Sieczkowska-Golub
Dorota Jarzebicka
Grzegorz Oracz
Jaroslaw Kierkus
World Journal of Gastroenterology, 2018, (35) : 4021 - 4027
[26] Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease
Peyrin-Biroulet, Laurent
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (26): : 2561 - 2561
[27] Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease
Nielsen, Ole Haagen
Ainsworth, Mark Andrew
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (08): : 754 - 762
[28] Failure Rate of Antitumor Necrosis Factor Alpha Biologics in Very Early Onset Inflammatory Bowel Disease
Collen, Lauren, V
Snapper, Scott B.
INFLAMMATORY BOWEL DISEASES, 2024, 30 (03) : 513 - 514
[29] Mucosal and Histologic Healing in Children With Inflammatory Bowel Disease Treated With Antitumor Necrosis Factor-Alpha
Scarallo, Luca
Alvisi, Patrizia
Bolasco, Giulia
Di Toma, Michele
Lanari, Marcello
Cangiari, Alice
Paci, Monica
Naldini, Sara
Renzo, Sara
Barp, Jacopo
De Masi, Salvatore
Lionetti, Paolo
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2021, 72 (05): : 728 - 735
[30] Does the Antitumor Necrosis Factor-α Therapy Decrease the Vertebral Fractures Occurrence in Inflammatory Bowel Disease?
Maldonado-Perez, M. B.
Castro-Laria, L.
Caunedo-Alvarez, A.
Montoya-Garcia, M. J.
Giner-Garcia, M.
Arguelles-Arias, F.
Romero-Gomez, M.
Vazquez-Gamez, M. A.
JOURNAL OF CLINICAL DENSITOMETRY, 2019, 22 (02) : 195 - 202

← 1 2 3 4 5 →